Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Agnes Ginges Centre for Molecular Cardiology, |
RCV000999601 | SCV001156304 | uncertain significance | Hypertrophic cardiomyopathy | 2018-10-15 | criteria provided, single submitter | research | This variant has been identified as part of our research program. Refer to the 'condition' field for the phenotype of the proband(s) identified with this variant. For further information please feel free to contact us. |
Labcorp Genetics |
RCV001858901 | SCV002294150 | likely benign | Duchenne muscular dystrophy | 2024-12-20 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004994186 | SCV005566443 | uncertain significance | Cardiovascular phenotype | 2024-11-04 | criteria provided, single submitter | clinical testing | The p.Q132R variant (also known as c.395A>G), located in coding exon 6 of the DMD gene, results from an A to G substitution at nucleotide position 395. The glutamine at codon 132 is replaced by arginine, an amino acid with highly similar properties. Based on data from gnomAD, the G allele has an overall frequency of 0.0005% (1/183380) total alleles studied, with 1 hemizygote(s) observed. The highest observed frequency was 0.0012% (1/81832) of European (non-Finnish) alleles. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |